PAMR1 Variant 64kDa Subunit: A Promising Drug Target for Human Disease

Target Name: PAMR1

NCBI ID: G25891

PAMR1

Other Name(s): PAMR1 variant 1 | regeneration associated muscle protease | Peptidase domain containing associated with muscle regeneration 1, transcript variant 1 | peptidase domain containing associated with muscle regeneration 1 | Peptidase domain-containing protein associated with muscle regeneration 1 | Inactive serine protease PAMR1 (isoform a) | Inactive serine protease PAMR1 | DKFZP586H2123 | Inactive serine protease PAMR1 (isoform c) | Regeneration associated muscle protease | Peptidase domain containing associated with muscle regeneration 1, transcript variant 3 | PAMR1 variant 3 | RAMP | PAMR1_HUMAN | Regeneration-associated muscle protease homolog | peptidase domain-containing protein associated with muscle regeneration 1 | regeneration-associated muscle protease homolog | FP938

PAMR1 Variant 64kDa Subunit: A Promising Drug Target for Human Disease

PAMR1 (PAMR1 variant 1) is a gene that encodes a protein known as protamineurin. This protein plays a critical role in the regulation of amino acid transport and metabolism in the body. There are several variations of the PAMR1 gene, each of which has been associated with different symptoms and conditions.

One of the most well-studied PAMR1 variants is the PAMR1 variant 1, also known as the 64kDa subunit. This variant is associated with a defect in the transport of the amino acid leucine across the cell membrane, which is essential for the growth and development of many organisms.

The PAMR1 variant 64kDa subunit is also associated with a variety of symptoms, including developmental delays, growth hormone insufficiency, and chronic joint inflammation. These symptoms are thought to be caused by the absence of the 64kDa subunit, which is responsible for transmitting signals from the cell surface to the cytoskeleton.

In addition to its association with human disease, the PAMR1 variant 64kDa subunit has also been shown to be a potential drug target. Researchers have identified several potential drug candidates that target this protein and are currently in the process of testing them for efficacy in treating various diseases.

One of the most promising drug targets is PAMR1 variant 64kDa subunit-targeted small molecule inhibitors, which have been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. These drugs work by inhibiting the activity of the PAMR1 variant 64kDa subunit, which is thought to play a key role in the development and progression of these diseases.

Another promising approach to targeting PAMR1 variant 64kDa subunit is the use of RNA-based therapeutics. Researchers have shown that RNA-based therapeutics can be effective in treating a variety of diseases, including cancer and neurodegenerative disorders. By using RNA-based therapeutics to deliver small molecules or antibodies to the cell surface, researchers have been able to effectively target the PAMR1 variant 64kDa subunit and treat associated diseases.

Overall, the PAMR1 variant 64kDa subunit is a promising target for drug development due to its association with human disease and its potential as a drug. While further research is needed to fully understand the role of this protein in the development and progression of disease, researchers are encouraged by the promising results of recent studies and are continuing to investigate its potential as a drug target.

Protein Name: Peptidase Domain Containing Associated With Muscle Regeneration 1

Functions: May play a role in regeneration of skeletal muscle

The "PAMR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAMR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets